Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.19.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Product sales, net $ 1,915,909 $ 1,805,605
Cost of products sold 618,694 562,676
Gross profit 1,297,215 1,242,929
Selling, general and administrative expenses 2,109,050 3,018,780
Research and development expenses 6,346 225,817
Total operating expenses 2,115,396 3,244,597
Loss from operations (818,181) (2,001,668)
Other expenses (2,264) (1,700)
Interest income 1,019 2,664
Change in fair value of derivative liability 40,260
Loss before provision for income taxes and net losses of equity investments (779,166) (2,000,704)
Provision for income taxes (4,465) (11,464)
Loss before equity in net earnings (losses) of equity investments (783,631) (2,012,168)
(Loss) earnings from China Joint Venture (9,564) 36,783
Net loss (793,195) (1,975,385)
Net loss attributable to noncontrolling interests (10,443) (101,407)
Net loss attributable to Milestone Scientific Inc. $ (782,752) $ (1,873,978)
Net loss per share applicable to common stockholders—    
Basic (in dollars per share) $ (0.02) $ (0.06)
Diluted (in dollars per share) $ (0.02) $ (0.06)
Weighted average shares outstanding and to be issued—    
Basic (in shares) 40,531,762 34,766,014
Diluted (in shares) 40,531,762 34,766,014